Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Trial Profile

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Anaesthesia; Postoperative pain
  • Focus Pharmacokinetics
  • Sponsors Pacira Pharmaceuticals
  • Most Recent Events

    • 20 May 2016 Dose of the EXPAREL is changed from 266 mg (20 mL) to 133 mg (10 mL).
    • 08 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 19 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top